about
sparfosic acidclevudinezanamiviraciclovirduvoglustatInterferon alfacon-1ledipasvirAmmothamninetenofovirbrefeldin Acytarabineinterferongrazoprevirtiloronefilipin IIIoseltamivirInterferon beta 1palmidroltrifluridineinterferon beta-1aVelpatasvirsofosbuvirKethoxalΔ12-PGJ2ditiocarbphosphonoacetic acidN-Hydroxyguanidinerupintrivir1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINEdisoxarilprostaglandin a1DL-selenocystineβ,γ-methylene guanosine 5'-triphosphatepseudohypericinTenuazonic acidcidofovir dihydrateentecavir hydrateconcanamycin Athymine arabinosideoxetanocin A
P2868
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (2013-03-31)HCV RAS Testing in Public Health ProgramsA Prospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV PneumoniaTreatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV InfectionA Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus InfectionThe Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 EpidemicA Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and CirrhosisAn Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis CThe Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2HCV + to HCV - Kidney TransplantBaricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.Anti-viral Effects of Azithromycin in Patients With Asthma and COPDEffects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical TrialSafety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
P4844
Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectivesEvaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-AnalysisAntiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination.A systematic review and meta-analysis to compare the efficacy of acyclovir 3% ophthalmic ointment to idoxuridine in curing herpetic keratitis by Day 7 of treatmentA Review of the Antiviral Role of Green Tea Catechins.Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.A scorpion venom peptide Ev37 restricts viral late entry by alkalizing acidic organellesConcentration of 2'C-methyladenosine triphosphate by enables specific inhibition of RNA virus 1 via its RNA polymeraseSofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and reviewPhospholipid regulation of innate immunity and respiratory viral infectionEvaluation of Efficacity and Safety of Oseltamivir and ZanamivirLong Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard TreatmentLong-Term Therapy With Ribavirin for Chronic Hepatitis CIn Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
P921
Q10851798-2852C8CF-7D36-4BBD-AE80-EACDA54EC3FBQ1100864-EE130283-05BC-4449-9913-DE9522B96667Q146075-E4C2FDC3-3BB5-47A8-9B40-099BEA32A290Q147101-7E53EC78-F7D1-4E22-A614-2EDE817F7477Q15274561-9F7DA8EB-E1DF-4F42-876C-07533F8B42DEQ15353101-7C3B1C48-9720-4623-AAF8-436030FBB5F3Q15409409-44F4D1DB-C3FE-4DDC-8957-5AFE79BC05F4Q15425294-94D2BA54-CB54-4C70-9138-3F14B41E545DQ155954-5C53C407-B34E-4744-983D-542FE664A935Q168790-62CAC46F-784A-4A67-BB58-BF91698AE20BQ180983-B0715F87-1EE9-439E-9774-E221710C7B25Q188269-E9EC7B9A-5ED2-4E29-A989-695E5EB100A1Q19786991-1DABAA0B-3E3A-411B-A887-A0DDC1CC364DQ2028068-82394369-B8C4-45C4-8165-30AD222991A9Q2073868-BBAB062A-6C25-4361-B9F1-729A6FDD653AQ211509-5106C4B1-790E-48D5-BEFF-A11BF647CFD3Q21173272-AF648A11-3E2D-46BB-B732-11725EE97496Q2159860-E6C34E64-C858-46B4-A208-7E2A957238B3Q2359590-249002AA-F8DD-457E-A889-1DFFDC2304BEQ2450337-B1DA77AF-38F6-48B4-AED4-7DCBDAADD447Q25018296-53B6A54D-FFC8-4843-AF34-A65133F1F6C0Q2502747-8077A5DD-8564-40DC-808A-B05A5BC029D5Q25112687-40F2E356-A7F2-4CB9-B8C9-D1DB56844E03Q27077015-F6F9C24F-48C9-403E-8420-483526C70AECQ27093504-6636B96A-A346-4843-86F9-966E5105845DQ27093778-6A969EC5-46C1-4394-9126-F9EA67F4EF46Q27094667-5E761CDE-A6AF-40CB-8081-BE1C15F93CD2Q27095569-35A97475-8929-4BD5-96FF-A377E66A504CQ27097100-A4C4C039-DD32-4EE8-B738-0623F4ADF357Q27097911-C58627B6-9912-460F-BA65-C4F743CB4AEAQ27098093-B0DAEA68-E8EA-4392-90F8-9208B6D16771Q27103768-92B2CFF1-A9BB-43E0-87A0-D74E45F970B5Q27105537-B2CD7B13-2D33-46FA-A96D-DBF34A259EA9Q27108109-715A7C61-DBC0-4BAE-BC46-71406B61E281Q27108395-4E0E3A72-6B7A-44F0-9408-85C2950D0836Q27126748-3734B876-46D1-4DCD-B0A1-0EA7509517E5Q27126952-DACA8198-8B59-4D03-88E5-7C4F4A481D95Q27140357-E3528E39-E19B-4747-8C25-3DAEFDECD707Q27149733-B8A996C5-AF91-4EF8-AE4E-DFBFA688E3E7Q27158845-B2E61BA4-6AD7-44C7-B0D7-682F26F4DF1B
P2868
Q86167643-0F4D41A7-5DC9-4915-B714-46B83C060013Q86241769-28AAC855-A07E-45B6-97DD-E6BA6D2AD7CBQ86260615-7861FD5C-0FD3-4FEC-8EC8-E04EBF811B46Q86268957-E2A6818C-3850-40D0-9F20-C010735A2FF6Q86287169-D26B0886-4A59-4A84-988F-09D662830BB8Q87930864-4EC1FEA6-F18A-48B5-970A-CD5EC89196CFQ87931271-8AC44324-3166-4263-90F4-2191DAEE2CE9Q87931783-1A0423F7-D144-4031-94FF-950D0B6C85CDQ87931817-9148D4F7-653C-49CC-B4EA-9522EFEEBA4DQ89154744-8C88222B-3EA7-45D2-A34F-016BC407E32EQ89154953-5B2D261D-2BCC-490B-86F1-E815D0C73501Q89154955-FF10E9E5-823E-4B0C-AF08-0EEFED11BFC5Q89155047-7DFFBC87-7FDB-4F4A-8727-C41062CEC993Q89435638-50923F35-5B96-4E3F-BD6A-9482867AF15DQ90693752-E3E41ED1-A51C-4693-A01F-5BFDD3A4E5B6
P4844
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Antivirales Agens
@de
agent antiviral
@ca
agent antiviral
@fr
agent antiviral
@ro
agente antiviral
@es
antiviral agent
@en
antiviralt middel
@nn
kontraŭvirusa agantaĵo
@eo
процівірусны агент
@be-tarask
عامل مضاد للفيروس
@ar
type
label
Antivirales Agens
@de
agent antiviral
@ca
agent antiviral
@fr
agent antiviral
@ro
agente antiviral
@es
antiviral agent
@en
antiviralt middel
@nn
kontraŭvirusa agantaĵo
@eo
процівірусны агент
@be-tarask
عامل مضاد للفيروس
@ar
altLabel
Antiviral Drugs
@en
Antivirals
@en
anti-viral agent
@en
anti-viral agents
@en
antiviral agents
@en
antiviralia
@nn
antiviralium
@nn
antivirusmiddel
@nn
антывірусны агент
@be-tarask
prefLabel
Antivirales Agens
@de
agent antiviral
@ca
agent antiviral
@fr
agent antiviral
@ro
agente antiviral
@es
antiviral agent
@en
antiviralt middel
@nn
kontraŭvirusa agantaĵo
@eo
процівірусны агент
@be-tarask
عامل مضاد للفيروس
@ar
P486
P683
P486
P672
D27.505.954.122.388
P7830
AntiviralAgents